Peripheral T cell lymphoma, not otherwise specified (PTCL‐NOS). A new prognostic model developed by the International T cell Project Network

Abstract

SummaryDifferent models to investigate the prognosis of peripheral T cell lymphoma not otherwise specified (PTCL‐NOS) have been developed by means of retrospective analyses. Here we report on a new model designed on data from the prospective T Cell Project. Twelve covariates collected by the T Cell Project were analysed and a new model (T cell score), based on four covariates (serum albumin, performance status, stage and absolute neutrophil count) that maintained their prognostic value in multiple Cox proportional hazards regression analysis was proposed. Among patients registered in the T Cell Project, 311 PTCL‐NOS were retained for study. At a median follow‐up of 46 months, the median overall survival (OS) and progression‐free survival (PFS) was 20 and 10 months, respectively. Three groups were identified at low risk (LR, 48 patients, 15%, score 0), intermediate risk (IR, 189 patients, 61%, score 1–2), and high risk (HiR, 74 patients, 24%, score 3–4), having a 3‐year OS of 76% [95% confidence interval 61–88], 43% [35–51], and 11% [4–21], respectively (P < 0·001). Comparing the performance of the T cell score on OS to that of each of the previously developed models, it emerged that the new score had the best discriminant power. The new T cell score, based on clinical variables, identifies a group with very unfavourable outcomes.

nm23, TOP2A and VEGF expression: Potential prognostic biologic factors in peripheral T‑cell lymphoma, not otherwise specified

“…Furthermore, most patients (77.4%) presented with extranodal sites of involvement, and 13.5% with ≥2 extranodal sites of involvement. It has been reported that the 3-year OS rate of PTCL-NOS was ~40% and the 5-year OS rate was ~30% (33,34). Recently, a small cohort study on a Japanese population with PTCL-NOS reported a 2-year OS rate of 61% (29).…”

“…Furthermore, it is considered that the IPI score does not provide specific biological insight or potential targets for drug therapy (28). Therefore, various prognostic models of PTCL-NOS have been investigated in previous studies, each of which incorporated different clinical parameters (31,34). Similar to IPI score, these prognostic models also did not include tumor-specific biological factors, and can therefore not be used for targeted therapies (31,34).…”

“…Therefore, various prognostic models of PTCL-NOS have been investigated in previous studies, each of which incorporated different clinical parameters (31,34). Similar to IPI score, these prognostic models also did not include tumor-specific biological factors, and can therefore not be used for targeted therapies (31,34). nm23, TOP2A, MUM-1 and VEGF are very common markers used to estimate the progression, infiltration and metastasis ability of many malignant tumors, particularly carcinomas (14,(40)(41)(42)(43)(44).…”

Ukraine Data on Prognostic Factors and Treatment Outcomes in Patients with Peripheral T-Cell Lymphomas

“…Data were censored if the patients were alive and free of progression/ relapse at last follow-up. Over all survival (OS) was defined as the Prognostic scores in PTCL One of the main ideas of this study was to analyze present prognostic scores: International Prognostic Index (IPI), Prognostic Index for T-cell lymphoma (PIT), International Peripheral T-cell lymphoma Project Score (IPTCLP), modified Prognostic Index for T-cell lymphoma -mPIT and the new one -T-cell score [10][11][12][13][14].…”

Efficacy of the GMALL‐B‐ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non‐Hodgkin‐lymphomas with or without CNS involvement

“…This goal is attained in the majority of patients diagnosed with BL andDLBCL. Favorable outcomes are less frequently seen in B-cell lymphomas transformed to a more aggressive histology after a preceding diagnosis of an indolent variant,12 mantle cell lymphomas,13 and lymphomas of T-cell origin 14. Well-established first-line treatment strategies comprise complex chemotherapy protocols employing (hyper)fractionated antimetabolites and alkylating agents as a backbone in BL, less complex protocols like CHOP and its variants in DLBCL and T-cell NHL and platinum/ antimetabolite containing regimens followed by high-dose chemotherapy with autologous stem cell support in MCL.…”